通过分子动力学模拟评估 MSH3 和 MSH6 多态性对接受铂类化疗的北印度患者肺癌风险的影响。
Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation.
发表日期：2024 Jul 13
作者：
Sidhartha Singh, Navneet Singh, Parth Sarthi Sen Gupta, Saroj Kumar Panda, Isha Dhamija, Deepak Nathiya, Sandeep Kumar, Siddharth Sharma
来源：
MOLECULAR & CELLULAR PROTEOMICS
摘要：
本研究调查了肺癌患者中 MSH3 和 MSH6 基因之间的关系。对肺癌患者和健康对照进行基因分型。计算优势比值并进行生存分析。 MSH6 多态性突变基因型 (TT) 患者患肺癌的风险是正常人的 1.5 倍 (p = 0.03)。对于非吸烟者来说，突变型基因型患肺癌的风险增加了三倍（p = 0.01）。接受多西紫杉醇和卡波/顺铂治疗且携带 MSH6 多态性 GT 基因型的患者报告中位生存时间缩短（4.9 个月与 9.13 个月）。 MSH3 和 MSH6 多态性参与调节肺癌风险。 MSH6 多态性与接受顺铂和多西他赛化疗的患者的高死亡率相关。© 2024。作者。
The present study investigated the relationship between MSH3 and MSH6 genes in lung cancer patients. Genotyping of lung cancer patients and healthy controls was performed. Odds ratio values were calculated and survival analysis performed. Patients with mutant genotype (TT) for MSH6 polymorphism have 1.5-fold risk for the development of lung cancer (p = 0.03). For non-smokers, the mutant-type genotype had a threefold increased risk of lung cancer (p = 0.01). Patients administered with docetaxel and carbo/cisplatin and carrying GT genotype for MSH6 polymorphism, patients reported a decrease in median survival time (4.9 vs 9.13 months). MSH3 and MSH6 polymorphisms are involved in modulating the risk towards lung cancer. MSH6 polymorphism is associated with high mortality rate for patients undergoing cisplatin and docetaxel chemotherapy.© 2024. The Author(s).